TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2942203
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg per day alternating every two weeks with medroxyprogesterone acetate (MPA) 1,000 mg per day orally.
Study: 2942203
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg per day and after relapse, high dosage of MPA alone.
Study: 25192980
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS combined with active venlafaxine (150‐225 mg/day)
Study: 25192980
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS combined with active venlafaxine (150‐225 mg/day)
Study: 22411689
Drug: DGLA-enriched oil
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGLA-enriched oil (450 mg as free DGLA) for 4 weeks
Study: 11949798
Drug: Scotchbond 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scotchbond 1 (dentin bonding agent)
Study: 9490250
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for Dupuytren contracture
Study: 3223639
Drug: 100 micrograms.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms.kg-1 morphine (group M)
Study: 3223639
Drug: 0.1 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml.kg-1 normal saline placebo (group T)
Study: 30115911
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg valproate
Study: 28508107
Drug: Memantine add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine add-on treatment
Study: 23047118
Drug: GS-9451 60
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 60 mg/day
Study: 23047118
Drug: GS-9451 200
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 200 mg/day
Study: 23047118
Drug: GS-9451 400
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 400 mg/day
Study: 23047118
Drug: GS-9451 200
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 200 mg/day (genotype 1b)
Study: 18466075
Drug: Ezetimibe (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (single dose with levothyroxine)
Study: 11090557
Drug: 0.45% oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% oral saline
Study: 11090557
Drug: No rehydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rehydration treatment
Study: 8937491
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of DMDC at 200 mg/m2 (initial dose) increased to 450 mg/m2.
Study: 8937491
Drug: Single repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single repeated administration of DMDC at 300 mg/m2.
Study: 8937491
Drug: 5-consecutive-day administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-consecutive-day administration of DMDC starting at 30 mg/m2/day increased to 40 mg/m2/day.
Study: 8937491
Drug: All administration
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All administration schedules of DMDC.
Study: 1530174
Drug: Clonidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (75 micrograms), followed by an infusion of 18.75 micrograms/h
Study: 17673455
Drug: Fresh sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh sperm from control group (normal patients >10(5) spermatozoa/ml)
Study: 11192874
Drug: ABT‐378 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐378 200 mg with ritonavir 100 mg every 12 h plus stavudine 40 mg and lamivudine 150 mg every 12 h (group I)
Study: 11192874
Drug: ABT‐378 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐378 400 mg with ritonavir 100 or 200 mg plus stavudine and lamivudine every 12 h (group II)
Study: 9626825
Drug: Hirudin (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (adjunctive therapy)
Study: 9626825
Drug: Heparin (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (adjunctive therapy)
Study: 3057956
Drug: Supplementary oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary oral nutrition for 3 months (Group 1)
Study: 28734660
Drug: CAN/AML combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN/AML combination therapy (8 mg/5 mg)
Study: 28734660
Drug: CAN/AML combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN/AML combination therapy (16 mg/5 mg)
Study: 28734660
Drug: CAN/AML combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN/AML combination therapy (16 mg/10 mg)
Study: 28734660
Drug: CAN (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN (8 mg)
Study: 28734660
Drug: AML (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML (10 mg)
Study: 28734660
Drug: AML (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML (5 mg)
Study: 21368745
Drug: Fresolimumab (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresolimumab (up to 4 mg/kg)
Study: 14571754
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 500 mg every 12 h
Study: 14571754
Drug: Intravenous cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefotaxime 2 g every 8 h
Study: 14571754
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 2 g every 24 h
Study: 7492038
Drug: Adenosine as
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine as a standing-order medication
Study: 7021071
Drug: Ibuprofen (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1600 mg, 400 mg every 6 hours)
Study: 28662676
Drug: BB‐12® containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB‐12® containing capsule (CAP)
Study: 25037968
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied from the first day of the conditioning regimen until day 7 post-HSCT
Study: 19364976
Drug: 1 portion
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 portion of fruit and vegetables daily
Study: 19364976
Drug: 3 portions
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 portions of fruit and vegetables daily
Study: 19364976
Drug: 6 portions
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 portions of fruit and vegetables daily
Study: 11464225
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg elemental Cu/day as CuSO4
Study: 11464225
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg elemental Cu/day as CuSO4
Study: 7995323
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with piretanide
Study: 7995323
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with ramipril
Study: 3219881
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg piretanide
Study: 7995323
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of ramipril and piretanide
Study: 3376144
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 ml/kg)
Study: 30665722
Drug: CVT-301 (levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT-301 (levodopa inhalation powder)
Study: 24061990
Drug: IMRT-TP (Intensity-Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT-TP (Intensity-Modulated Radiation Therapy plus chemotherapy with docetaxel and cisplatin)
Study: 24061990
Drug: IMRT (Simple
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT (Simple Intensity-Modulated Radiation Therapy)
Study: 15996667
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion with arithmetic increase
Study: 15996667
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion with geometric increase
Study: 12086732
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release Ibifen (200 mg)
Study: 12086732
Drug: Orudis retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orudis retard (200 mg)
Study: 12086732
Drug: Prompt release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt release Ibifen (100 mg, two 12-h doses)
Study: 9864078
Drug: Gabapentin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (mean daily dose: 3,646.15 mg)
Study: 8666093
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg loading dose, followed by 200 mg o.d.)
Study: 8666093
Drug: Amoxycillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin-clavulanic acid (500/125 mg t.i.d.)
Study: 8666093
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 g b.i.d.)
Study: 25691671
Drug: ET-B (bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-B (bevacizumab 15 mg/kg every 3 weeks + endocrine therapy)
Study: 19661810
Drug: HPV-16 therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16 therapeutic vaccine
Study: 14765636
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride (0.5% fluoride ion) followed by argon laser
Study: 11552048
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, 50 mg/day)
Study: 11552048
Drug: Dipyridamole (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (sustained-release preparation 400 mg/day)
Study: 8981292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and dipyridamole
Study: 8471228
Drug: Intravenous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rHuEPO (IV)
Study: 8471228
Drug: Subcutaneous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEPO (SC)
Study: 29910056
Drug: Allogeneic mesenchymal
Normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic mesenchymal stromal cells (allo‐MSCs) via 20 transendocardial injections
Study: 29910056
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) via 20 transendocardial injections
Study: 24733462
Drug: BMS-791325 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-791325 (100, 300, 600, or 900 mg)
Study: 24733462
Drug: BMS-791325 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-791325 (900 mg)
Study: 20466313
Drug: RCTs published
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCTs published in other journals (European Journal of Oral Sciences, Journal of Dentistry, Clinical Oral Investigations)
Study: 17900584
Drug: Sacrospinous suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacrospinous suspension (SS)
Study: 920496
Drug: Chlordiazepoxide treatment
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlordiazepoxide treatment for alcohol withdrawal
Study: 920496
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol treatment for alcohol withdrawal
Study: 31573666
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin formulation PT1 (2 strains of C. acnes SLST type C3 and K8, 50% each)
Study: 31573666
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin formulation PT2 (4 strains of C. acnes SLST type C3 [55%], K8 [5%], A5 [30%] and F4 [10%])
Study: 31573666
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide gel (active induction phase, 7 days)
Study: 19748761
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus NMES for four weeks (daily stimulation to both thighs for up to 30 minutes, frequency 50Hz, 'on' cycle 11%-25%)
Study: 17013637
Drug: Buprenorphine/naloxone (B/N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (B/N) 8/2 mg
Study: 17013637
Drug: Buprenorphine/naloxone (B/N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (B/N) 16/4 mg
Study: 17013637
Drug: Buprenorphine/naloxone (B/N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (B/N) 32/8 mg
Study: 15232046
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (12 weekly sessions)
Study: 11371692
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice daily from 36‐38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post‐partum)
Study: 3524797
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (IDM)
Study: 31629306
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of amino acid mixture twice daily for 7 days
Study: 29141739
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (2.7 × 10^5 PfSPZ)
Study: 27307526
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage MTX (7.5 mg/week)
Study: 27307526
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage MTX (20 mg/week)
Study: 25491622
Drug: Continuous blood
Normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous blood purification in combination with ulinastatin
Study: 25491622
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (oxygen inhalation, dynamic ECG monitoring, physical cooling methods)
Study: 18650153
Drug: Ixabepilone 40
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 40 mg/m2 plus capecitabine 1650-2000 mg/m2 (schedule A)
Study: 18650153
Drug: Ixabepilone 8-10
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 8-10 mg/m2 plus capecitabine 1650 mg/m2 (schedule B)
Study: 18650153
Drug: Grade 3/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 3/4 treatment-related events in phase II
Study: 16882128
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate 6 mg
Study: 12514275
Drug: Beta-carotene (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (24 mg/d from an algal source)
Study: 12514275
Drug: Carotenoid mix
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid mix (24 mg/d consisting of beta-carotene, lutein, and lycopene at 8 mg/d each)
Study: 8622025
Drug: Taxol (paclitaxel)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxol (paclitaxel) at a starting dose of 170 mg/m2 (135 mg/m2 for patients with prior pelvic radiation), given as a 24-hour continuous intravenous infusion every 3 weeks; dose adjustments allowed (escalations to 200 mg/m2 and deescalations to 110 mg/m2).
Study: 1496731
Drug: 5.1-[NANP]19 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1-[NANP]19 vaccine (50 or 400 micrograms doses)
Study: 27334739
Drug: UMEC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 62.5 mcg added to ICS/LABA
Study: 12959271
Drug: Remikiren 200
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 200 mg
Study: 7769797
Drug: Remikiren 300
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 300 mg
Study: 7769797
Drug: Remikiren 600
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 600 mg
Study: 12959271
Drug: Remikiren 800
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 800 mg
Study: 12959271
Drug: Remikiren (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (various doses)
Study: 2882766
Drug: Temazepam 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 0.5, 1.0 and 1.5 mg kg‐1 in an elixir formulation
Study: 2882766
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 3 mg kg‐1 in a syrup
Study: 31464933
Drug: Acupuncture in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture in combination with prokinetic drugs
Study: 31464933
Drug: Routine ICU
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine ICU treatment (Control)
Study: 28669169
Drug: Age, tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, tumor size, tumor grade at diagnosis, hormone receptor status of estrogen and progesterone, Her-2
Study: 26860019
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg intravenous 10 min before surgery)
Study: 21732218
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (0.625 mg/day of conjugated equine estrogens)
Study: 14705155
Drug: Anorexia nervosa
Normalized name: Syzygium nervosum flower bud extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anorexia nervosa treatment study
Study: 11194932
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression test modified with octreotide
Study: 3098417
Drug: 6-hour iv
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-hour iv infusion of recombinant interferon-gamma (rIFN-gamma) at doses ranging from 0.016 to 0.65 mg/m2/day
Study: 3098417
Drug: 24-hour iv
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour iv infusion of recombinant interferon-gamma (rIFN-gamma) at doses ranging from 0.01 to 0.05 mg/m2/day
Study: 30055991
Drug: Bilateral erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral erector spinae plane (ESP) block with 3 mg/kg of 0.375% ropivacaine before anesthesia induction
Study: 30055991
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 gm every 6 hours) and tramadol (50 mg every 8 hours) intravenously
Study: 30527177
Drug: Platinum-pemetrexed (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-pemetrexed (intravenous every 3 weeks for up to six cycles)
Study: 27150079
Drug: Diazepam administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam administration (7-8 days)
Study: 7848898
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous nitroglycerin infusion for the first 48 hours after acute MI
Study: 7848898
Drug: Prolonged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged therapy with nitrates spanning the healing phase of acute anterior Q-wave MI
Study: 7848898
Drug: Long-term nitrate
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term nitrate therapy in patients with suspected MI
Study: 3396474
Drug: Single-dose cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cefotaxime (1g)
Study: 29794563
Drug: Continuous sciatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sciatic nerve blockade with 5 ml/h ropivacaine 0.2% (CO)
Study: 29794563
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection sciatic nerve blockade with 5 ml/h saline infusion (SIN)
Study: 29794563
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection sciatic nerve blockade (SIN)
Study: 26568249
Drug: Grape Seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape Seed Extract (GSE) 300 mg/d (150 mg twice daily) for 6 weeks
Study: 26568249
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg GSE) for 6 weeks
Study: 25870665
Drug: Intravitreal administration
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal administration of triamcinolone acetonide
Study: 25870665
Drug: Intravitreal administration
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal administration of triamcinolone acetonide in combination with bevacizumab